| | | Overall (n = 376) | 1L pre-October 2016 cohort (n = 97) | 1L post-October 2016 cohort (n = 279) | value | Overall (n = 196) | 2L pre-October 2016 cohort (n = 77) | 2L post-October 2016 cohort (n = 119) | value |
| | Median age at 1L initiation (years, min, max) | 62 (20, 90+) | 62 (25, 84) | 62 (20, 90+) | 0.9460 | 60 (21, 86) | 60 (30, 82) | 61 (21, 86) | 0.8195 | | Male, n (%) | 182 (48.4) | 50 (51.5) | 132 (47.3) | 0.4722 | 90 (45.9) | 38 (49.4) | 52 (43.7) | 0.4380 | | Race, n (%) | | | | 0.8902 | | | | 0.8028 | | Caucasian | 28 (76.3) | 74 (76.3) | 213 (76.3) | 144 (73.5) | 56 (72.7) | 88 (74.0) | | Black or African American | 27 (7.2) | 6 (6.2) | 21 (7.5) | 16 (8.2) | 6 (7.8) | 10 (8.4) | | Others | 15 (4.0) | 5 (5.2) | 10 (3.6) | 9 (4.6) | 5 (6.5) | 4 (3.4) | | No information | 47 (12.5) | 12 (12.4) | 35 (12.5) | — | 27 (13.8) | 10 (13.0) | 17 (14.3) | — | | BMI, n (%) | | | | 0.7285 | | | | 0.8281 | | Underweight (BMI < 18.5) | 9 (2.4) | 1 (1.0) | 8 (2.9) | 5 (2.6) | 1 (1.3) | 4 (3.4) | | Normal (BMI: 18.5 - < 25) | 104 (27.7) | 27 (27.8) | 77 (27.6) | 50 (25.5) | 20 (26.0) | 30 (25.2) | | Overweight (BMI: 25– < 30) | 116 (30.9) | 33 (34.0) | 83 (29.7) | 56 (28.6) | 24 (31.2) | 32 (26.9) | | Obese (BMI = 30+) | 147 (39.1) | 36 (37.1) | 111 (39.8) | 85 (43.4) | 32 (41.6) | 53 (44.5) | | | ECOG score, n (%) | | | | 0.8993 | | | | 0.8161 | | 0 | 62 (16.5) | 17 (17.5) | 45 (16.1) | 38 (19.4) | 15 (19.5) | 23 (19.3) | | 1 | 221 (58.8) | 57 (58.8) | 164 (58.8) | 116 (59.2) | 45 (58.4) | 71 (59.7) | | 2 | 39 (10.4) | 8 (8.2) | 31 (11.1) | 13 (6.6) | 7 (9.1) | 6 (5.0) | | 3 | 2 (0.5) | 0 (0.00) | 2 (0.7) | 1 (0.5) | 0 (0.00) | 1 (0.8) | | No information | 52 (13.8) | 15 (15.5) | 37 (13.3) | — | 28 (14.3) | 10 (13.0) | 18 (15.1) | — | | Diagnosis, n (%) | | | | 0.6024 | | | | 0.3299 | | Sarcoma | 213 (56.6) | 56 (57.7) | 157 (56.3) | 107 (54.6) | 41 (53.2) | 66 (55.5) | | Leiomyosarcoma | 83 (22.1) | 25 (25.8) | 58 (20.8) | 45 (23.0) | 23 (29.9) | 22 (18.5) | | Uterine sarcoma | 52 (13.8) | 12 (12.4) | 40 (14.3) | 30 (15.3) | 10 (13.0) | 20 (16.8) | | Fibrosarcoma | 14 (3.7) | 1 (1.0) | 13 (4.7) | 8 (4.1) | 1 (1.3) | 7 (5.9) | | Chondrosarcoma | 8 (2.1) | 2 (2.1) | 6 (2.2) | 3 (1.5) | 1 (1.3) | 2 (1.7) | | Rhabdomyosarcoma | 6 (1.6) | 1 (1.0) | 5 (1.8) | 3 (1.5) | 1 (1.3) | 2 (1.7) | | Histology, n (%) | | | | 0.1641 | | | | 0.1871 | | Angiosarcoma | 11 (2.9) | 8 (8.2) | 3 (1.1) | 7 (3.6) | 6 (7.8) | 1 (0.8) | | Fibroblastic/myofibroblastic | 10 (2.7) | 2 (2.1) | 8 (2.9) | 7 (3.6) | 2 (2.6) | 5 (4.2) | | Leiomyosarcoma | 87 (23.1) | 40 (41.2) | 47 (16.8) | 62 (31.6) | 35 (45.5) | 27 (22.7) | | Liposarcoma | 16 (4.3) | 4 (4.1) | 12 (4.3) | 9 (4.6) | 3 (3.9) | 6 (5.0) | | Nerve sheath sarcoma | 4 (1.1) | 2 (2.1) | 2 (0.7) | 1 (0.5) | 0 (0.00) | 1 (0.8) | | Others | 25 (6.6) | 7 (7.2) | 18 (6.5) | 15 (7.7) | 4 (5.2) | 11 (9.2) | | Rhabdomyosarcoma | 10 (2.7) | 5 (5.2) | 5 (1.8) | 7 (3.6) | 4 (5.2) | 3 (2.5) | | Synovial | 8 (2.1) | 4 (4.1) | 4 (1.4) | 6 (3.1) | 3 (3.9) | 3 (2.5) | | Undifferentiated pleomorphic sarcoma | 36 (9.6) | 19 (19.6) | 17 (6.1) | 24 (12.2) | 14 (18.2) | 10 (8.4) | | Documented unknown | 4 (1.1) | 2 (2.1) | 2 (0.7) | — | 3 (1.5) | 2 (2.6) | 1 (0.8) | — | | No information | 165 (43.9) | 4 (4.1) | 161 (57.7) | — | 55 (28.1) | 4 (5.2) | 51 (42.9) | — | | Tumor location, n (%) | | | | 0.5625 | | | | 0.8542 | | Axilla | 1 (0.3) | 1 (1.0) | 0 (0.00) | 1 (0.5) | 1 (1.3) | 0 (0.00) | | Breast | 2 (0.5) | 2 (2.1) | 0 (0.00) | 2 (1.0) | 2 (2.6) | 0 (0.00) | | Genitourinary | 5 (1.3) | 2 (2.1) | 3 (1.1) | 5 (2.6) | 2 (2.6) | 3 (2.5) | | Head or neck | 8 (2.1) | 5 (5.2) | 3 (1.1) | 4 (2.0) | 3 (3.9) | 1 (0.8) | | Lower limb | 47 (12.5) | 24 (24.7) | 23 (8.2) | 33 (16.8) | 18 (23.4) | 15 (12.6) | | Mediastinum, lung, pleura | 5 (1.3) | 3 (3.1) | 2 (0.7) | 4 (2.0) | 3 (3.9) | 1 (0.8) | | Others | 44 (11.7) | 19 (19.6) | 25 (9.0) | 29 (14.8) | 13 (16.9) | 16 (13.4) | | Pelvis | 5 (1.3) | 2 (2.1) | 3 (1.1) | 4 (2.0) | 2 (2.6) | 2 (1.7) | | Retroperitoneal | 20 (5.3) | 8 (8.2) | 12 (4.3) | 11 (5.6) | 7 (9.1) | 4 (3.4) | | Trunk | 10 (2.7) | 4 (4.1) | 6 (2.2) | 6 (3.1) | 3 (3.9) | 3 (2.5) | | Upper limb | 16 (4.3) | 5 (5.2) | 11 (3.9) | 10 (5.1) | 4 (5.2) | 6 (5.0) | | Uterus | 45 (12.0) | 16 (16.5) | 29 (10.4) | 29 (14.8) | 13 (16.9) | 16 (13.4) | | Documented unknown | 3 (0.8) | 2 (2.1) | 1 (0.4) | — | 3 (1.5) | 2 (2.6) | 1 (0.8) | — | | No information | 165 (43.9) | 4 (4.1) | 161 (57.7) | — | 55 (28.1) | 4 (5.2) | 51 (42.9) | — | | Tumor grade, n (%) | | | | 0.5287 | | | | 0.4477 | | Well differentiated | 17 (4.5) | 4 (4.1) | 13 (4.7) | 6 (3.1) | 2 (2.6) | 4 (3.4) | | Moderately differentiated | 47 (12.5) | 15 (15.5) | 32 (11.5) | 27 (13.8) | 13 (16.9) | 14 (11.8) | | Poorly differentiated | 158 (42.0) | 45 (46.4) | 113 (40.5) | 83 (42.3) | 36 (46.8) | 47 (39.5) | | Undifferentiated | 5 (1.3) | 1 (1.0) | 4 (1.4) | 2 (1.0) | 0 (0.00) | 2 (1.7) | | No information | 149 (39.6) | 32 (33.0) | 117 (41.9) | — | 78 (39.8) | 26 (33.8) | 52 (43.7) | — | | Count of metastatic sites, n (%) | | | | <0.0001 | | | | 0.3188 | | 0 | 137 (36.4) | 16 (16.5) | 121 (43.4) | 54 (27.6) | 16 (20.8) | 38 (31.9) | | 1 | 127 (33.8) | 40 (41.2) | 87 (31.2) | 73 (37.2) | 28 (36.4) | 45 (37.8) | | 2 | 71 (18.9) | 24 (24.7) | 47 (16.8) | 46 (23.5) | 20 (26.0) | 26 (21.8) | | 3 | 29 (7.7) | 11 (11.3) | 18 (6.5) | 15 (7.7) | 8 (10.4) | 7 (5.9) | | 4 | 7 (1.9) | 3 (3.1) | 4 (1.4) | 3 (1.5) | 2 (2.6) | 1 (0.8) | | 5 | 5 (1.3) | 3 (3.1) | 2 (0.7) | 5 (2.6) | 3 (3.9) | 2 (1.7) | | Bone, n (%) | 46 (12.2) | 18 (18.6) | 28 (10.0) | 0.0274 | 28 (14.3) | 14 (18.2) | 14 (11.8) | 0.2099 | | Bowel, n (%) | 4 (1.1) | 1 (1.0) | 3 (1.1) | 1.0000 | 2 (1.0) | 1 (1.3) | 1 (0.8) | 1.0000 | | Brain, n (%) | 3 (0.8) | 0 (0.00) | 3 (1.1) | 0.5720 | 1 (0.5) | 0 (0.00) | 1 (0.8) | 1.0000 | | Colon, n (%) | 3 (0.8) | 1 (1.0) | 2 (0.7) | 1.0000 | 1 (0.5) | 1 (1.3) | 0 (0.00) | 0.3929 | | Lymph node, n (%) | 37 (9.8) | 17 (17.5) | 20 (7.2) | 0.0032 | 20 (10.2) | 10 (13.0) | 10 (8.4) | 0.3005 | | Soft tissue, n (%) | 18 (4.8) | 7 (7.2) | 11 (3.9) | 0.1933 | 12 (6.1) | 5 (6.5) | 7 (5.9) | 0.8616 | | Liver, n (%) | 47 (12.5) | 16 (16.5) | 31 (11.1) | 0.1673 | 30 (15.3) | 14 (18.2) | 16 (13.4) | 0.3684 | | Lung, n (%) | 149 (39.6) | 54 (55.7) | 95 (34.1) | 0.0002 | 89 (45.4) | 43 (55.8) | 46 (38.7) | 0.0183 | | Skin, n (%) | 8 (2.1) | 3 (3.1) | 5 (1.8) | 0.4303 | 4 (2.0) | 3 (3.9) | 1 (0.8) | 0.3019 | | Other sites of, n (%) | 94 (25.0) | 31 (32.0) | 63 (22.6) | 0.0661 | 60 (30.6) | 24 (31.2) | 36 (30.3) | 0.8918 |
|
|
1L, first-line; 2L, second-line; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; Min, minimum; Max, maximum; SD, standard deviation. Variable assessed among patients selected for chart review ( n = 211). |
